Comparative Pharmacology
Head-to-head clinical analysis: CICLOPIROX versus FOCINVEZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CICLOPIROX versus FOCINVEZ.
CICLOPIROX vs FOCINVEZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciclopirox is a hydroxypyridone antifungal agent that chelates polyvalent metal cations (e.g., Fe3+, Al3+) inhibiting metal-dependent enzymes, thereby disrupting fungal cellular metabolic processes, including mitochondrial electron transport and energy production.
FOCINVEZ is a small-molecule inhibitor of the interaction between the N-terminal domain of the androgen receptor (AR) and the AR N-terminal domain coactivator binding site, thereby blocking AR-mediated gene transcription and inhibiting prostate cancer cell growth.
Ciclopirox 8% nail lacquer: Apply to affected nails once daily for up to 48 weeks. Ciclopirox 1% cream or lotion: Apply to affected skin twice daily for 2-4 weeks. Ciclopirox 1% shampoo: Apply to wet hair, lather, leave for 3 minutes, rinse; use twice weekly for 4 weeks (for seborrheic dermatitis).
Intravenous: 1.5 mg/kg every 6 hours; maximum single dose: 200 mg.
None Documented
None Documented
Clinical Note
moderateCiclopirox + Tranilast
"The risk or severity of adverse effects can be increased when Ciclopirox is combined with Tranilast."
Clinical Note
moderateCiclopirox + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Ciclopirox is combined with Tolfenamic acid."
Clinical Note
moderateCiclopirox + Nimesulide
"The risk or severity of adverse effects can be increased when Ciclopirox is combined with Nimesulide."
Clinical Note
moderateCiclopirox + Risedronic acid
Terminal elimination half-life: 1.7-3.0 hours in healthy individuals; prolonged in hepatic impairment
Terminal elimination half-life: 12-15 hours; allows twice-daily dosing in most patients, extended in renal impairment (up to 30-40 hours in severe impairment).
Renal: approximately 70-80% of the absorbed dose as unchanged drug and glucuronide conjugates; biliary/fecal: ~20-30%
Renal: 70% (unchanged drug), Biliary/Fecal: 20% (metabolites), Other: 10% (minor pathways).
Category A/B
Category C
Antifungal
Antifungal
"The risk or severity of adverse effects can be increased when Ciclopirox is combined with Risedronic acid."